02.07.2017 Products

Humco Hormone Concentrate Program Noted in International Journal of Pharmaceutical Compounding as Aid for Meeting USP<800> Standards

AUSTIN, February 7, 2017 – Humco, a diversified global pharmaceutical company, announced today that a new article in the January/February 2017 issue of the International Journal of Pharmaceutical Compounding (IJPC) names Humco’s Hormone Concentrate Program (HCP) as an available aid for meeting future standards as set forth by United States Pharmacopeia Chapter <800> Hazardous Drugs – Handling in Healthcare Setting (USP<800>). The article, titled “Basics of Compounding with Dilutions and Concentrates,” offers multiple examples of how compounding pharmacies may protect their pharmacists and technicians in compliance with USP<800> while saving time and money.

Humco’s HCP is a program in which hazardous drugs, such as the sex hormones Estrone, Estradiol, Estriol, Progesterone, and Testosterone, are manufactured as bulk concentrates for further prescription compounding. These hormones are incorporated in certain amounts into Humco’s HRT Heavy™ base, which is specifically designed for male and female hormone restoration formulations and has a low to moderate API carrying capacity. Incorporating the hormones into the HRT Heavy base prevents the formation of dust from the hormones, which can be hazardous if inhaled.

In order to meet specific patient needs, pharmacies should further dilute the concentrates by adding additional base and/or active pharmaceutical ingredients (APIs). Humco offers a calculator tool to assist its customers in properly determining the correct ratios of concentrate and base.

To find the full article from IJPC and learn more about meeting USP<800> standards, please click here.

To learn more about Humco’s Hormone Concentrate Program and how Humco can help you comply with USP<800>, please call a Humco representative at 855-925-4736.


Humco, founded in 1872, is a diversified global pharmaceutical company. Humco is focused on developing, manufacturing and commercializing innovative pharmaceuticals and high-quality over-the-counter medicines for patients around the world.

With headquarters in Austin, TX, Humco serves over 45,000 pharmacies through its Pharmaceutical Segment and its Consumer OTC Products franchise. The Company is anchored by its leading non-sterile compounding delivery vehicles, including topical and transdermal creams and syrups and suspensions. Humco also serves consumers through its established and diverse Consumer OTC Products business of over 160 items with product placement in all major chains, grocery, mass retailers and independent pharmacies. Humco’s leading team of professionals have strong expertise ranging from product development to commercialization in the Company’s state-of-the-art FDA registered, cGMP compliant facilities.

With a presence in approximately 20 countries, Humco is committed to working with pharmacists, physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Humco’s website at www.humco.com.